ProCE Banner Activity

Podcast Pearls
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

PDF
Download this PDF summary transcript of experts’ answers to questions posed during a live symposium on hemophilia A management.

Released: January 18, 2022

Expiration: January 17, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Mark Reding

Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Guy A. Young

Guy A. Young, MD

Professor of Pediatrics
University of Southern California
Keck School of Medicine
Director
Hemostasis and Thrombosis Center
Childrens Hospital Los Angeles
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme

Takeda Pharma USA Inc Takeda Onc Co

Faculty Disclosure

Primary Author

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received funds for research support from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure (paid to institution) and consulting fees from CSL Behring, BioMarin, Genentech/Roche, HEMA Biologics , Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda.

Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Mark Reding, MD, has disclosed that he has received consulting fees from Bayer, CSL Behring, Novo Nordisk, Sanofi Genzyme, and Takeda; funds for research support from Bayer and Biomarin; and fees for non-CME/CE services from Bayer, CSL Behring, Sanofi Genzyme, and Takeda.

Guy A. Young, MD

Professor of Pediatrics
University of Southern California
Keck School of Medicine
Director
Hemostasis and Thrombosis Center
Childrens Hospital Los Angeles
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche; fees for non-CME/CE services from Bioverativ, Genentech/Roche, and Sanofi; and consulting fees from CSL-Behring, Genentech/Roche, Grifols, Hema Biologics, Kedrion, Novo Nordisk, Sanofi, Spark, and Takeda.